TX200 Archives - Renal Interventions

First patient dosed in study evaluating TX200 cell therapy product for...

5th April 2022

Sangamo Therapeutics has announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200—an investigational, wholly owned, autologous chimeric antigen...

Write to us
Editor: George Barker [email protected]
Advertising: Rav Pankhania [email protected]

United Kingdom:

BIBA Medical, Europe
526 Fulham Road, Fulham, London, SW6 5NR
TEL: +44 (0)20 7736 8788
Email: [email protected]

United States:

BIBA Medical, North America
155 North Wacker Drive, Suite 4250, Chicago, IL 60606
TEL: +1 949 723 9309
Email: [email protected]

Terms and Conditions | Privacy Policy

Tag: TX200

First patient dosed in study evaluating TX200 cell therapy product for...